 WATERTOWN, Mass.--BUSINESS WIRE--SQZ Biotechnologies Company NYSE: SQZ, focused on unlocking the full potential of cell therapies for multiple therapeutic areas, is presenting preclinical results from the companys Tolerizing Antigen Carrier TAC program demonstrating that its engineered TACs can drive antigen-specific immune tolerance through key mechanisms relevant to many complex autoimmune diseases. In models of Type 1 diabetes T1D, SQZTM TACs were able to delete antigen-specific T ce 